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223REPLY: Patent Foramen Ovale and
Paradoxical Systemic Embolism:
Can We Determine High-Risk Characteristics
by Echocardiography?We appreciate the comments by Dr. Ren and col-
leagues on our review of paradoxical embolism and
related diagnosis and treatment (1) and their insights
on their experience with intracardiac echocardiogra-
phy (ICE). Although ICE provides detailed anatomic
information of intracardiac structures, including the
atrial septum, it is mainly used as an intraprocedural
guide and imaging tool in complex cardiac in-
terventions. Conversely, it does not qualify as a
diagnostic screening examination in patients with
cryptogenic embolism for the detection of interatrial
shunts. First, ICE is an invasive imaging modality that
requires the insertion of an 8-F catheter probe into
the venous circulation, which can be associated
with periprocedural complications such as bleeding,
hematoma, and thrombosis. Second, studies com-
paring ICE with transesophageal echocardiography or
transcranial Doppler studies have failed to show
improved accuracy and effectiveness in the detection
of interatrial shunts (2). Third, the use of ICE is
associated with signiﬁcant costs related to the
expensive, disposable imaging catheters.
Although there are no standardized recommenda-
tions to fully describe the anatomic and physiological
characteristics of the patent foramen ovale (PFO),
several echocardiographic high-risk criteria for the
recurrence of paradoxical embolism have been iden-
tiﬁed. As recently conﬁrmed by the RoPE (Risk of
Paradoxical Embolism) investigators, a signiﬁcant
atrial septal aneurysm with an interatrial septal
excursion during a cardiac cycle of $10 mm repre-
sents a strong risk factor for recurrent stroke in the
presence of a PFO (3). In addition, larger anatomic
and physiological size of the PFO has been associated
with an increased risk of recurrent stroke (4). Along
this line, it has been suggested that the mechanism by
which atrial septal aneurysms increase the risk of
stroke in the presence of a PFO is directly related to alarger PFO size. Considering the intrauterine func-
tion of the Eustachian valve, which directs oxygen-
ated venous blood from the inferior vena cava
preferentially to the PFO, it is plausible that particu-
larly in patients with residual, prominent remnants of
the Eustachian valve, the latter presents a risk factor
for recurrence of stroke. Finally, we wish to point to
the growing body of evidence highlighting important
differences in performance and effectiveness of
available PFO closure devices to prevent recurrent
embolic events that should be taken into consider-
ation when evaluating the beneﬁt of percutaneous
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